Market Summary
USD31.95+0.12
Market Closed0.38%
ZLAB Stock Price
ZLAB RSI Chart
ZLAB Valuation
ZLAB Price/Sales (Trailing)
ZLAB Profitability
ZLAB Fundamentals
ZLAB Revenue
ZLAB Earnings
Price Action
52 Week Range
20.9853.95
(Low)(High)
Last 7 days
1.4%
Last 30 days
-7.8%
Last 90 days
-10.1%
Trailing 12 Months
6.5%
ZLAB Financial Health
ZLAB Investor Care
Financials for Zai Lab
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | 7.5% | 231,114,000 | 215,040,000 | 196,611,000 | 182,174,000 | 170,933,000 |
| S&GA Expenses | 2.1% | 264,490,000 | 258,971,000 | 256,524,000 | 248,971,000 | 239,984,000 |
| R&D Expenses | -1.9% | 281,026,000 | 286,408,000 | 391,548,000 | 347,168,000 | 423,308,000 |
| EBITDA | 25.6% | -434,838,000 | -584,637,000 | -520,108,000 | -545,684,000 | - |
| EBITDA Margin | 32.0% | -2.02 | -2.97 | -2.86 | -3.19 | - |
| Earnings Before Taxes | 7.5% | -410,036,000 | -443,065,000 | -592,612,000 | -527,494,000 | -552,482,000 |
| EBT Margin | 31.6% | -2.06 | -3.01 | -2.90 | -3.23 | - |
| Interest Expenses | - | 0.00 | - | - | - | - |
| Net Income | 7.5% | -410,036,000 | -443,286,000 | -593,342,000 | -528,564,000 | -553,955,000 |
| Net Income Margin | 31.7% | -2.06 | -3.02 | -2.90 | -3.24 | - |
| Free Cahsflow | 10.4% | -392,227,000 | -437,894,000 | -472,046,000 | -493,213,000 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Assets | -4.1% | 1,170 | 1,220 | 1,299 | 1,419 | 1,501 |
| Current Assets | -4.6% | 1,072 | 1,124 | 1,210 | 1,336 | 1,393 |
| Cash Equivalents | -12.8% | 880 | 1,008 | 1,119 | 681 | 847 |
| Inventory | 21.5% | 38.00 | 32.00 | 29.00 | 23.00 | 20.00 |
| Net PPE | 0.8% | 58.00 | 58.00 | 51.00 | 46.00 | 45.00 |
| Liabilities | -3.3% | 169 | 175 | 193 | 207 | 193 |
| Current Liabilities | -10.9% | 125 | 140 | 156 | 169 | 155 |
| Shareholder's Equity | -4.2% | 1,001 | 1,046 | 1,106 | 1,212 | 1,308 |
| Retained Earnings | -2.6% | -1,910 | -1,861 | -1,799 | -1,638 | -1,500 |
| Additional Paid-In Capital | 0.6% | 2,911 | 2,893 | 2,877 | 2,857 | 2,839 |
| Accumulated Depreciation | 6.2% | 20.00 | 19.00 | 18.00 | - | - |
| Shares Outstanding | 0.4% | 964 | 960 | 960 | 958 | 957 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Cashflow From Operations | 4.9% | -349 | -367 | -411 | -445 | -466 |
| Share Based Compensation | 6.9% | 66.00 | 61.00 | 58.00 | 50.00 | 46.00 |
| Cashflow From Investing | -5.7% | 396 | 420 | 143 | -631 | -522 |
| Cashflow From Financing | -239.5% | -5.87 | -1.73 | -1.81 | -2.99 | 821 |
Risks for ZLAB
What is the probability of a big loss on ZLAB?
86.9%
Probability that Zai Lab stock will be more than 20% underwater in next one year
57.7%
Probability that Zai Lab stock will be more than 30% underwater in next one year.
41.9%
Probability that Zai Lab stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ZLAB drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Zai Lab was unfortunately bought at previous high price.
Drawdowns
Returns for ZLAB
Cumulative Returns on ZLAB
5.3%
5-Year Cumulative Returns
-22.1%
3-Year Cumulative Returns
What are the long-term rolling returns for ZLAB?
FIve years rolling returns for Zai Lab.
Annualized Returns
Which funds bought or sold ZLAB recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 20.69 | 161,487 | 686,487 | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 212 | 6,688,000 | 9,495,000 | -% |
2023-05-18 | INTERNATIONAL BIOTECHNOLOGY TRUST PLC | unchanged | - | 202,922 | 2,626,140 | 0.73% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -1.38 | 1,000 | 21,000 | -% |
2023-05-17 | Advisory Services Network, LLC | unchanged | - | 128 | 1,663 | -% |
2023-05-16 | RBF Capital, LLC | unchanged | - | 37,900 | 498,900 | 0.04% |
2023-05-16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | reduced | -48.19 | -716,070 | 916,280 | -% |
2023-05-16 | JANE STREET GROUP, LLC | sold off | -100 | -746,194 | - | -% |
2023-05-16 | Rockefeller Capital Management L.P. | sold off | -100 | - | - | -% |
2023-05-16 | Susquehanna International Group Ltd. | new | - | 958,121 | 958,121 | 0.54% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Zai Lab News
Schedule 13G FIlings of Zai Lab
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | qiming venture partners iv, l.p. | 8.1% | 79,229,320 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 0.6% | 5,701,440 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 0.00% | 0 | SC 13G/A | |
| Jul 05, 2022 | baillie gifford & co | 4.79% | 46,935,800 | SC 13G/A | |
| Feb 14, 2022 | qiming venture partners iv, l.p. | 8.2% | 7,922,932 | SC 13G/A | |
| Feb 14, 2022 | du ying | 4.78% | 4,742,042 | SC 13G/A | |
| Feb 14, 2022 | invesco ltd. | 7.6% | 7,286,493 | SC 13G | |
| Feb 11, 2022 | capital world investors | 5.5% | 5,294,950 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A |
ZLAB Fair Value
Recent SEC filings of Zai Lab
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 09, 2023 | 10-Q | Quarterly Report | |
| May 09, 2023 | 8-K | Current Report | |
| May 01, 2023 | ARS | ARS | |
| Apr 28, 2023 | DEF 14A | DEF 14A | |
| Apr 18, 2023 | PRE 14A | PRE 14A | |
| Apr 05, 2023 | 4 | Insider Trading | |
| Apr 05, 2023 | 4 | Insider Trading | |
| Apr 05, 2023 | 4 | Insider Trading | |
| Apr 05, 2023 | 4 | Insider Trading | |
| Apr 05, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for ZLAB
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-04-03 | Cho William Ki Chul | acquired | - | - | 2,827 | chief financial officer |
2023-03-31 | Reinhart Harald | sold (taxes) | -35,222 | 33.26 | -1,059 | see remarks |
2023-03-31 | Edmondson Frazor Titus III | sold (taxes) | -31,696 | 33.26 | -953 | chief legal officer |
2023-03-31 | Du Ying | acquired | 472,292 | 33.26 | 14,200 | chairperson & ceo |
2023-03-31 | Du Ying | sold (taxes) | -185,857 | 33.26 | -5,588 | chairperson & ceo |
2023-03-31 | Reinhart Harald | acquired | 144,614 | 33.26 | 4,348 | see remarks |
2023-03-31 | Edmondson Frazor Titus III | acquired | 116,410 | 33.26 | 3,500 | chief legal officer |
2023-03-06 | Du Ying | gifted | - | - | -852 | chairperson & ceo |
2023-03-06 | Du Ying | sold (taxes) | -4,902,740 | 40.55 | -120,906 | chairperson & ceo |
2023-03-06 | Du Ying | acquired | 180,000 | 0.6 | 300,000 | chairperson & ceo |
About Zai Lab
Ying Du
1950
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
ZLAB Income Statement
2023-03-31Unaudited Condensed Consolidated Statements of Operations - USD ($) | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
| Revenues: | ||
| Product revenue, net | $ 62,797,000 | $ 46,095,000 |
| Collaboration revenue | 0 | 629,000 |
| Total revenues | 62,797,000 | 46,724,000 |
| Expenses: | ||
| Cost of sales | (21,337,000) | (15,643,000) |
| Research and development | (48,472,000) | (53,854,000) |
| Selling, general, and administrative | (62,510,000) | (56,991,000) |
| Loss from operations | (69,522,000) | (79,764,000) |
| Interest income | 10,232,000 | 188,000 |
| Foreign currency gain | 8,912,000 | 2,285,000 |
| Other income (expenses), net | 1,234,000 | (4,882,000) |
| Loss before income tax and share of loss from equity method investment | (49,144,000) | (82,173,000) |
| Income tax expense | 0 | 0 |
| Share of loss from equity method investment | 0 | (221,000) |
| Net loss | (49,144,000) | (82,394,000) |
| Net loss attributable to ordinary shareholders - basic | (49,144,000) | (82,394,000) |
| Net loss attributable to ordinary shareholders - diluted | $ (49,144,000) | $ (82,394,000) |
| Loss per share/ADS - basic (in dollars per share) | $ (0.05) | $ (0.09) |
| Loss per share/ADS - diluted (in dollars per share) | $ (0.05) | $ (0.09) |
| Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - basic (in shares) | 961,444,780 | 955,499,030 |
| Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - diluted (in shares) | 961,444,780 | 955,499,030 |
| American Depositary Shares | ||
| Expenses: | ||
| Loss per share/ADS - basic (in dollars per share) | $ (0.51) | $ (0.86) |
| Loss per share/ADS - diluted (in dollars per share) | $ (0.51) | $ (0.86) |
| Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - basic (in shares) | 96,144,478 | 95,549,903 |
| Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - diluted (in shares) | 96,144,478 | 95,549,903 |
ZLAB Balance Sheet
2023-03-31Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 879,844 | $ 1,008,470 |
| Short-term investments | 50,550 | 0 |
| Accounts receivable (net of allowance for credit loss of $13 and $11 as of March 31, 2023 and December 31, 2022, respectively) | 43,346 | 39,963 |
| Notes receivable | 17,381 | 8,608 |
| Inventories, net | 38,405 | 31,621 |
| Prepayments and other current assets | 42,772 | 35,674 |
| Total current assets | 1,072,298 | 1,124,336 |
| Restricted cash, non-current | 1,003 | 803 |
| Long term investments (including the fair value measured investment of $6,872 and $6,431 as of March 31, 2023 and December 31, 2022, respectively) | 6,872 | 6,431 |
| Prepayments for equipment | 1,721 | 1,396 |
| Property and equipment, net | 58,309 | 57,863 |
| Operating lease right-of-use assets | 20,148 | 19,512 |
| Land use rights, net | 6,920 | 6,892 |
| Intangible assets, net | 1,479 | 1,511 |
| Long-term deposits | 1,324 | 1,396 |
| Total assets | 1,170,074 | 1,220,140 |
| Current liabilities: | ||
| Accounts payable | 66,361 | 65,974 |
| Current operating lease liabilities | 7,318 | 7,050 |
| Other current liabilities | 50,881 | 66,818 |
| Total current liabilities | 124,560 | 139,842 |
| Deferred income | 30,968 | 21,360 |
| Non-current operating lease liabilities | 12,979 | 13,343 |
| Other non-current liabilities | 325 | 0 |
| Total liabilities | 168,832 | 174,545 |
| Commitments and contingencies (Note 15) | ||
| Shareholders’ equity | ||
| Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 967,197,350 and 962,455,850 shares issued as of March 31, 2023 and December 31, 2022, respectively; 963,688,740 and 960,219,570 shares outstanding as of March 31, 2023 and December 31, 2022, respectively) | 6 | 6 |
| Additional paid-in capital | 2,911,454 | 2,893,120 |
| Accumulated deficit | (1,910,504) | (1,861,360) |
| Accumulated other comprehensive income | 17,272 | 25,685 |
| Treasury Stock (at cost, 3,508,610 and 2,236,280 shares as of March 31, 2023 and December 31, 2022, respectively) | (16,986) | (11,856) |
| Total shareholders’ equity | 1,001,242 | 1,045,595 |
| Total liabilities and shareholders’ equity | $ 1,170,074 | $ 1,220,140 |